Seres Therapeutics, Inc. (MCRB) stock
MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.41+0.00 (0.00%)
Close on Nov 17, 2026Market cap $14.02MP/E –Yield –
Seres Therapeutics cash
Cash and short-term investments held at the end of each period.
Seres Therapeutics's cash was $15.59M at Jun 30, 2026. For fiscal 2025 it was $45.77M, up 16.0% from the year before. Over ten years it grew -13.9% a year on average. The highest annual figure on record is $298.71M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.77M | +16.0% |
| FY2024 | Dec 31, 2024 | $39.46M | -71.0% |
| FY2023 | Dec 31, 2023 | $136.15M | -28.2% |
| FY2022 | Dec 31, 2022 | $189.53M | -36.6% |
| FY2021 | Dec 31, 2021 | $298.71M | +17.8% |
| FY2020 | Dec 31, 2020 | $253.62M | +167.5% |
| FY2019 | Dec 31, 2019 | $94.82M | +10.3% |
| FY2018 | Dec 31, 2018 | $85.93M | -42.7% |
| FY2017 | Dec 31, 2017 | $150.10M | -34.7% |
| FY2016 | Dec 31, 2016 | $230.00M | +12.1% |
| FY2015 | Dec 31, 2015 | $205.08M | +79.6% |
| FY2014 | Dec 31, 2014 | $114.19M | +6803.6% |
| FY2013 | Dec 31, 2013 | $1.65M | -73.4% |
| FY2012 | Dec 31, 2012 | $6.22M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $15.59M | -71.1% |
| Q1 FY2026 | Mar 31, 2026 | $29.83M | -55.8% |
| Q4 FY2025 | Dec 31, 2025 | $45.77M | +16.0% |
| Q3 FY2025 | Sep 30, 2025 | $47.64M | -37.9% |
| Q2 FY2025 | Jun 30, 2025 | $54.05M | -33.4% |
| Q1 FY2025 | Mar 31, 2025 | $67.52M | -43.6% |
| Q4 FY2024 | Dec 31, 2024 | $39.46M | -71.0% |
| Q3 FY2024 | Sep 30, 2024 | $76.70M | -56.9% |
| Q2 FY2024 | Jun 30, 2024 | $81.11M | -65.9% |
| Q1 FY2024 | Mar 31, 2024 | $119.61M | +4.3% |
| Q4 FY2023 | Dec 31, 2023 | $136.15M | -28.2% |
| Q3 FY2023 | Sep 30, 2023 | $178.10M | -26.2% |
| Q2 FY2023 | Jun 30, 2023 | $237.71M | +16.5% |
| Q1 FY2023 | Mar 31, 2023 | $114.73M | -55.2% |
| Q4 FY2022 | Dec 31, 2022 | $189.53M | -36.6% |
| Q3 FY2022 | Sep 30, 2022 | $241.19M | -30.6% |
| Q2 FY2022 | Jun 30, 2022 | $203.98M | -4.9% |
| Q1 FY2022 | Mar 31, 2022 | $256.19M | -6.0% |
| Q4 FY2021 | Dec 31, 2021 | $298.71M | +17.8% |
| Q3 FY2021 | Sep 30, 2021 | $347.39M | +8.5% |
| Q2 FY2021 | Jun 30, 2021 | $214.55M | +235.6% |
| Q1 FY2021 | Mar 31, 2021 | $272.55M | +262.9% |
| Q4 FY2020 | Dec 31, 2020 | $253.62M | +167.5% |
| Q3 FY2020 | Sep 30, 2020 | $320.31M | +282.3% |
| Q2 FY2020 | Jun 30, 2020 | $63.94M | -37.5% |
| Q1 FY2020 | Mar 31, 2020 | $75.09M | +39.8% |
| Q4 FY2019 | Dec 31, 2019 | $94.82M | +10.3% |
| Q3 FY2019 | Sep 30, 2019 | $83.79M | +14.9% |
| Q2 FY2019 | Jun 30, 2019 | $102.34M | +6.5% |
| Q1 FY2019 | Mar 31, 2019 | $53.71M | -56.6% |
| Q4 FY2018 | Dec 31, 2018 | $85.93M | -42.7% |
| Q3 FY2018 | Sep 30, 2018 | $72.90M | -57.4% |
| Q2 FY2018 | Jun 30, 2018 | $96.10M | -43.9% |
| Q1 FY2018 | Mar 31, 2018 | $123.71M | -38.8% |
| Q4 FY2017 | Dec 31, 2017 | $150.10M | -34.7% |
| Q3 FY2017 | Sep 30, 2017 | $171.30M | -15.8% |
| Q2 FY2017 | Jun 30, 2017 | $171.21M | – |
| Q1 FY2017 | Mar 31, 2017 | $202.17M | – |
| Q4 FY2016 | Dec 31, 2016 | $230.00M | – |
| Q3 FY2016 | Sep 30, 2016 | $203.38M | – |
See a number that looks wrong?